INTRODUCTION {#s1}
============

Phosphatase and tensin homolog (*PTEN*) is also known as mutated in multiple advanced cancers 1 (*MMAC1*) or TGF-β regulated and epithelial cell-enriched phosphatase 1 (*TEP1*) and is a tumor suppressor gene \[[@R1]--[@R3]\]. It is located on human chromosome 10q23 and encodes a 403 amino acid protein that is associated with lipid and protein associated phosphoinositide 3-phosphatase activity. PTEN is generally cytosolic and regulates phosphatidylinositol 3,4,5-trisphosphate (PIP3) levels; small fraction of PTEN is recruited to the plasma membrane \[[@R4]\]. PTEN reduces PIP3 levels \[[@R5]\], which decreases mTOR/AKT signaling pathway that is critical for cancer cell growth, survival and progression \[[@R6], [@R7]\].

Single-nucleotide polymorphisms (SNPs) are the most common type of genetic variations that involve change in a single nucleotide in a gene or associated genetic elements, which affect gene expression \[[@R8]\]. A number of SNPs have been implicated in various human diseases \[[@R9]--[@R13]\] and are clinically relevant as factors that determine cancer susceptibility, prognosis of survival, and treatment response \[[@R8]\]. A number of SNPs, mutations and deletions in *PTEN* have been reported in many human cancers including glioblastoma \[[@R14]--[@R19]\].

The relationship between cancer risk and two *PTEN* SNPs, rs701848 and rs2735343 is controversial. The rs701848 SNP is associated with increased risk of breast cancer (BC) \[[@R20]\], renal cell cancer (RCC) \[[@R21]\], colorectal cancer (CRC) \[[@R22]\], and esophageal squamous cell cancer (ESCC) \[[@R23]\]. However, there are contradictory reports that show no correlation between rs701848 and the risk of ESCC \[[@R24]\] and hepatocellular carcinoma (HCC) \[[@R25]\]. Moreover, rs2735343 is associated with increased breast cancer risk in early onset and familial cases \[[@R26]\]. Subjects with rs2735343 (GG) are associated with elevated risk of ESCC \[[@R23]\]. However, there is no association between rs2735343 (G/C) and the risk of endometrial cancer \[[@R27]\]. In this meta-analysis, we estimated the association between cancer susceptibility and the *PTEN* SNPs, rs701848 and rs2735343.

RESULTS {#s2}
=======

Literature search and eligibility criteria {#s2_1}
------------------------------------------

We searched the PubMed, EMBASE, Cochrane library and the national knowledge infrastructure of China (CNKI) databases and identified 1230 articles. After removing the duplicate articles, 892 articles still remained for further evaluation. Then, we reviewed article titles and abstracts and excluded 839 reports that were not related to cancer risk and *PTEN* SNPs. We then assessed the remaining 53 reports in greater detail and excluded 35 articles that did not satisfy the eligibility criteria. Finally, 18 eligible case-control studies were included in our meta-analysis \[[@R20]--[@R37]\] (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). Moreover, we analyzed the data of each SNP independently in studies that investigated both rs701848 and rs2735343 SNPs \[[@R23], [@R24], [@R32], [@R33]\]. Overall, we analyzed 5458 cases and 6003 controls for rs701848 in 14 studies as well as 5490 cases and 6209 controls for rs2735343 in 8 studies.

![Flow diagram of study selection process](oncotarget-08-96290-g001){#F1}

###### Characteristics of studies on the associations between rs701848(C/T) and rs2735343(C/G) polymorphisms in PTEN and cancer

  Author      Year   Country           Ethnicity            Cancer type    Genotyping method              Source of controls   P value for HWE ^q^   Case/control   Frequency distributions of the genotypes                                  
  ----------- ------ ----------------- -------------------- -------------- ------------------------------ -------------------- --------------------- -------------- ------------------------------------------ -------- ----- ------ -------- -----
  rs701848                                                                                                                                                          TT                                         TC       CC    TT     TC       CC
  Li          2017   China             Asian                BC **^c^**     TaqMan **^l^**                 HB **°**             0.22559               880/910        215                                        468      197   273    474      163
  Lin         2015   China             Asian                CRC **^d^**    TaqMan                         HB                   0.32525               780/764        186                                        421      173   229    397      138
  Xu          2015   China             Asian                ESCC **^e^**   TaqMan                         PB **^p^**           0.19999               425/446        205                                        182      38    243    182      21
  Jing        2014   China             Asian                CRC            SNPscan **^m^**                PB                   0.26281               519/537        190                                        253      94    162    272      85
  Jang        2013   China             Asian                ESCC           PCR-RFLP **^n^**               PB                   0.0306                304/413        91                                         155      58    183    165      65
  Ma          2012   China             Asian                ESCC           PCR-RFLP                       PB                   0.20173               226/226        70                                         121      35    103    90       33
  Cao         2012   China             Asian                RCC **^f^**    TaqMan                         HB                   0.52099               710/760        222                                        338      150   277    351      132
  Chen        2012   China             Asian                PC **^g^**     TaqMan                         HB                   0.81281               666/708        212                                        329      125   235    353      120
  Ding        2011   China             Asian                HCC **^h^**    PCR-RFLP                       PB                   0.32694               131/215        43                                         67       21    65     116      34
  Hiroshi     2009   Japan             Asian                PC             PCR-RFLP                       HB                   0.51513               140/167        51                                         58       31    47     90       30
  Song        2009   China             Asian                LC **^i^**     PCR-RFLP                       HB                   0.92453               149/104        46                                         74       29    26     54       24
  Liu         2009   China             Asian                GC **^j^**     PCR-RFLP                       HB                   0.92453               58/104         17                                         35       6     24     54       26
  Liu         2008   China             Asian                LC             PCR-RFLP                       HB                   0.92453               91/104         29                                         45       17    26     54       24
  Rajaraman   2007   American          Mixed-race **^a^**   Glioma         TaqMan                         HB                   0.98643               379/545        138                                        184      57    190    262      93
  rs2735343                                                                                                                                                         GG                                         GC       CC    GG     GC       CC
  Chen        2016   China             Asian                BC             SNPscan                        HB                   0.53023               728/669        190                                        360      178   142    348      179
  Jang        2013   China             Asian                ESCC           PCR-RFLP                       PB                   0.07336               304/413        108                                        151      45    93     181      139
  Ma          2012   China             Asian                ESCC           PCR-RFLP                       PB                   0.38422               226/226        71                                         117      38    45     100      81
  Slattery    2012   Mexico American   Mixed race **^b^**   BC             multiplexed bead array assay   PB                   \-                    3590/4183      1398                                       2192\*   \-    1491   2692\*   \-
  Lacey       2011   Poland            Caucasian            EC **^k^**     Infinium assay                 PB                   0.47144               416/406        211                                        163      42    215    154      37
  Song        2009   China             Asian                GC             PCR-RFLP                       HB                   0.51145               58/104         4                                          33       21    30     57       17
  Shi         2009   China             Asian                Lung cancer    PCR-RFLP                       HB                   0.54184               77/104         32                                         37       8     29     57       18
  Liu         2008   China             Asian                LC             PCR-RFLP                       HB                   0.54184               91/104         29                                         46       16    18     57       29

^a^ Mixed-race consists of White, non-Hispanic, Hispanic, and Black; ^b^ Mixed-race consists of Hispanic, native American, and NHW (non-Hispanic white) women; ^c^ BC, breast cancer; ^d^ CRC, colorectal cancer; ^e^ ESCC, esophageal squamous cell carcinoma; ^f^ RCC, renal cell carcinoma; ^g^ PC, prostate carcinoma; ^h^ HCC, hepatocellular carcinoma; ^i^ LC, laryngocarcinoma; ^j^ GC, gastric cancer; ^k^ EC, endometrial cancer ; ^l^ TaqMan, TaqMan SNP Genotyping Assays; ^m^ SNPscan, SNPscanGenotyping system; ^n^ PCR-RFLP, Polymerase chain reaction (PCR)--restriction fragment length polymorphism assays; ° HB, hospital-based; ^p^ PB, population-based; ^q^ HWE, Hardy-Weinberg equilibrium; \* The number of GC/CC is 2192 in cases, 2692 in controls.

Study characteristics {#s2_2}
---------------------

Table [1](#T1){ref-type="table"} summarizes the main characteristics of the included studies such as first author, published year, country of origin where the study was conducted, ethnicity, cancer type, genotyping method, source of controls, and frequency distributions of the genotypes for cases and controls (Table [1](#T1){ref-type="table"}). Among the 18 studies, 14 were conducted in China and 1 each in Japan, USA, Poland, and Mexico/USA. Overall, 15 out of 18 studies enrolled Asian subjects, 1 study enrolled Caucasian individuals, and 2 studies enrolled subjects from mixed races. The cancer types that were analyzed in these studies included colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), prostate carcinoma (PC), laryngocarcinoma (LC), gastric cancer (GC), breast cancer (BC), glioma, and endometrial cancer (EC). PTEN genotyping was performed by Taqman (6 studies), Polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP; 8 studies), SNPscan (2 studies), Infinium assay (1 study) and multiplexed bead arrays (1study). Among the 18 studies, 10 were hospital-based (HB) and 8 were public-based (PB). In 16 out of 18 eligible studies, genotype distributions of rs701848 and rs2735343 in the controls were in agreement with Hardy-Weinberg equilibrium (HWE). The P value for Jang\'s study \[[@R23]\] was less than 0.05, whereas there was no available data to calculate P value for HWE in Slattery\'s study \[[@R28]\]. The genomic DNA was isolated from blood samples in 17 out of 18 included studies, whereas in Slattery\'s study \[[@R28]\] whole blood or mouthwash samples were used for isolating genomic DNA. The quality scores according to Newcastle-Ottawa quality assessment scale varied 6 to 9 in the 18 studies (Figure [2](#F2){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

![Quality assessment scale of eligible studies](oncotarget-08-96290-g002){#F2}

Association between *PTEN* SNPs and cancer risk {#s2_3}
-----------------------------------------------

We analyzed the association between the *PTEN* SNPs and cancer risk using dominant, recessive, heterozygous, homozygous, and additive models. The rs701848 CC genotype was associated with 1.169-fold increased cancer risk in recessive model (OR = 1.169, 95% CI: 1.061-1.288, Table [2](#T2){ref-type="table"}, Figure [3D](#F3){ref-type="fig"}). However, it was not associated with cancer risk in heterozygous (OR = 1.099, 95% CI: 0.943 - 1.280), homozygous (OR = 1.190, 95% CI: 0.990 - 1.432), dominant (OR = 1.115, 95% CI: 0.959 - 1.297) and additive (OR = 1.088, 95% CI: 0.990 - 1.196) models (Table [2](#T2){ref-type="table"}, Figure [3A-3C, 3E](#F3){ref-type="fig"}). The rs2735343 GG genotype showed increased cancer risk in the dominant model (OR = 0.758, 95% CI: 0.590 - 0.972, Table [2](#T2){ref-type="table"}, Figure [4C](#F4){ref-type="fig"}). The rs2735343 GG polymorphism was not associated with cancer risk in heterozygous (OR = 0.821, 95% CI: 0.625 - 1.079), homozygous (OR = 0.642, 95% CI: 0.349 - 1.180), recessive (OR = 0.711, 95% CI: 0.437 - 1.156), and additive (OR = 0.802, 95% CI: 0.594 - 1.083) models (Table [2](#T2){ref-type="table"}, Figure [3A, 3B, 3D, 3E](#F3){ref-type="fig"}).

###### ORs and 95% CI for cancers and rs701848 or rs2735343 polymorphism in PTEN under different genetic models

  Genetic models                    n    OR (95% CI)           *P* (OR)   Model (method)   I-square (%)   *P* (H)   *P* (Begg)   *P* (Egger)
  --------------------------------- ---- --------------------- ---------- ---------------- -------------- --------- ------------ -------------
  ***rs701848***                                                                                                                 
  Heterozygous model (TC *vs* TT)   14   1.099(0.943,1.280)    0.226      R                65.5           0.000     0.228        0.305
  Homozygous model (CC *vs* TT)     14   1.190(0.990,1.432)    0.064      R                57.5           0.004     0.037        0.054
  Dominant model (TC+CC *vs* TT)    14   1.115(0.959,1.297)    0.157      R                68.4           0.000     0.274        0.154
  Recessive model (CC *vs* CT+TT)   14   1.169(1.061,1.288)    0.002      F                29.5           0.141     0.012        0.060
  Additive (C *vs* T)               14   1.088(0.990,1.196)    0.080      R                63.5           0.001     0.101        0.066
  ***rs2735343***                                                                                                                
  Heterozygous model (GC *vs* GG)   7    0.821(0.625,1.079)    0.157      R                61.6           0.016     0.764        0.800
  Homozygous model (CC *vs* GG)     7    0.642(0.349,1.180)    0.154      R                87.8           0.000     0.368        0.796
  Dominant model (GC+CC *vs* GG)    8    0.758(0.590, 0.972)   0.029      R                78.5           0.000     1.000        0.614
  Recessive model (CC *vs* GC+GG)   7    0.711(0.437,1.156)    0.169      R                86.6           0.000     0.548        0.974
  Additive (C *vs* G)               7    0.802(0.594,1.083)    0.150      R                89.1           0.000     0.368        0.909

OR, odds ratio; CI, confidence intervals; *P* (OR), *P* for heterogeneity; *P* (H), *P* for heterogeneity; n, number of included studies; R, random-effect model; F, fixed-effect method.

![Forest plot of cancer risk associated with rs701848 (T\>C) models\
**(A)** heterozygous model; **(B)** homozygous model; **(C)** dominant model; **(D)** recessive model; **(E)** additive model.](oncotarget-08-96290-g003){#F3}

![Forest plot of cancer risk associated with rs2735343 (G\>C) models\
**(A)** heterozygous model; **(B)** homozygous model; **(C)** dominant model; **(D)** recessive model; **(E)** additive model.](oncotarget-08-96290-g004){#F4}

The pooled odds ratio (OR) for rs701848 polymorphism in recessive model was analyzed by fixed-effects model. Since data was heterogeneous, random effects model was used to analyze the significance of pooled OR for rs701848 in homozygous, heterozygous, dominant, and recessive models and in all models for rs2735343 (Table [2](#T2){ref-type="table"}).

Subgroup analysis {#s2_4}
-----------------

We performed subgroup analysis based on ethnicity, cancer type, source of controls, genotyping methods, quality score (at the median cut-off point of 8), and sample size, respectively. We observed that Asian individuals with rs701848 C allele were associated with 1.105-fold increased cancer risk than the non-Asian population (C vs T, OR = 1.105, 95% CI: 1.003 - 1.217, Table [3](#T3){ref-type="table"}). The CC genotype showed 1.234-fold and 1.185-fold higher cancer risk respectively in homozygous (CC vs TT, OR = 1.234, 95% CI: 1.024 - 1.488) and recessive (CC vs CT+TT, OR = 1.185, 95% CI: 1.049 - 1.338, Table [3](#T3){ref-type="table"}) models in the Asian population. Asian individuals with rs2735343 GG genotype were also associated with increased risk of cancer (Table [4](#T4){ref-type="table"}). Regarding cancer types, the rs701848 CC genotype showed 1.813-fold increased ESCC risk than the rs701848 TT genotype (CC vs. TT, OR = 1.813, 95% CI: 1.352 - 2.433, Table [3](#T3){ref-type="table"}). There was no association between *PTEN* SNPs and cancer risk in all models of rs701848 in regard to hospital or public based studies (Table [3](#T3){ref-type="table"}).

###### Subgroup analyses of rs701848 polymorphism in PTEN with cancer risk

  Subgroups                       TC *vs* TT             CC vs TT               TC+CC *vs* TT   CC *vs* CT+TT          C *vs* T                                                                                                                                                                                 
  ------------------- ----------- ---------------------- ---------------------- --------------- ---------------------- ---------------------- ------- ---------------------- ---------------------- ------- ---------------------- ---------------------- ------- ---------------------- ---------------------- -------
  Ethnicity           Asian       13                     1.110 (0.942, 1.308)   0.214           13                     1.234 (1.024, 1.488)   0.027   13                     1.132 (0.965, 1.329)   0.128   13                     1.185 (1.049, 1.338)   0.006   13                     1.105 (1.003, 1.217)   0.043
  Non-Asian           1           0.967 (0.724, 1.291)   0.820                  1               0.844 (0.568, 1.254)   0.401                  1       0.935 (0.711, 1.229)   0.628                  1       0.860 (0.601, 1.232)   0.412                  1       0.928 (0.768, 1.122)   0.441                  
  Cancer type         ESCC        3                      1.609 (1.140, 2.272)   0.007           3                      1.813 (1.352, 2.433)   0.000   3                      1.612 (1.240, 2.096)   0.000   3                      1.358 (0.982, 1.880)   0.065   3                      1.375 (1.206, 1.567)   0.000
  Other               11          1.004 (0.874, 1.154)   0.952                  11              1.077 (0.881, 1.315)   0.471                  11      1.014 (0.874, 1.176)   0.855                  11      1.113 (0.972, 1.274)   0.120                  11      1.026 (0.930, 1.133)   0.606                  
  Source of control   PB          5                      1.249 (0.863, 1.808)   0.238           5                      1.387 (0.983, 1.959)   0.063   5                      1.270 (0.902, 1.788)   0.171   5                      1.207 (0.988, 1.476)   0.066   5                      1.187 (0.979, 1.438)   0.081
  HB                  9           1.060 (0.919, 1.222)   0.425                  9               1.097 (0.870, 1.383)   0.433                  9       1.060 (0.905, 1.242)   0.470                  9       1.106 (0.938, 1.304)   0.229                  9       1.043 (0.933, 1.166)   0.461                  
  Genotyping          mic-Array   7                      1.103 (0.972, 1.252)   0.129           7                      1.293 (1.061, 1.576)   0.011   7                      1.144 (0.997, 1.314)   0.056   7                      1.214 (1.065, 1.384)   0.004   7                      1.123 (1.023, 1.232)   0.015
  PCR-RFLP            7           1.040 (0.698, 1.552)   0.846                  7               0.964 (0.648, 1.435)   0.857                  7       1.013 (0.691, 1.484)   0.948                  7       0.986 (0.766, 1.270)   0.913                  7       0.996 (0.795, 1.248)   0.973                  
  Sample size         \<500       6                      0.924 (0.614, 1.391)   0.706           6                      0.852 (0.583, 1.246)   0.409   6                      0.900 (0.617, 1.314)   0.586   6                      0.912 (0.683, 1.218)   0.532   6                      0.928 (0.751, 1.148)   0.493
  ≥500                8           1.161 (0.996, 1.354)   0.057                  8               1.337 (1.109, 1.613)   0.002                  8       1.202 (1.029, 1.403)   0.020                  8       1.219 (1.085, 1.369)   0.001                  8       1.151 (1.046, 1.267)   0.004                  
  Quality score       \<8         6                      0.920 (0.720, 1.176)   0.506           6                      0.851 (0.565, 1.281)   0.439   6                      0.897 (0.687, 1.171)   0.425   6                      0.936 (0.684, 1.280)   0.678   6                      0.923 (0.762, 1.117)   0.410
  ≥8                  8           1.213 (0.996, 1.478)   0.054                  8               1.367 (1.142, 1.636)   0.001                  8       1.248 (1.038, 1.501)   0.018                  8       1.225 (1.087, 1.380)   0.001                  8       1.175 (1.061, 1.300)   0.002                  

###### Subgroup analyses of rs2735343 polymorphism in PTEN with cancer risk

  Subgroups                       GC *vs* GG             CC *vs* GG             GC+CC *vs* GG   CC *vs* GC+GG          C *vs* G                                                                                                                                                                                 
  ------------------- ----------- ---------------------- ---------------------- --------------- ---------------------- ---------------------- ------- ---------------------- ---------------------- ------- ---------------------- ---------------------- ------- ---------------------- ---------------------- -------
  Ethnicity           Asian       6                      0.765 (0.565, 1.036)   0.083           6                      0.577 (0.292, 1.139)   0.113   6                      0.684 (0.468, 1.001)   0.050   6                      0.658 (0.379, 1.141)   0.136   6                      0.760 (0.543, 1.064)   0.110
  Non-Asian           1           1.079 (0.806, 1.443)   0.611                  1               1.157 (0.715, 1.871)   0.553                  2       0.939 (0.758, 1.162)   0.562                  1       1.120 (0.704, 1.782)   0.633                  1       1.081 (0.874,1.339)    0.472                  
  Source of control   PB          3                      0.855 (0.645, 1.134)   0.278           3                      0.458 (0.183, 1.148)   0.096   4                      0.749 (0.559, 1.005)   0.054   3                      0.514 (0.248, 1.063)   0.072   3                      0.676 (0.417, 1.095)   0.112
  HB                  4           0.853 (0.470, 1.550)   0.603                  4               0.902 (0.325, 2.507)   0.843                  4       0.868 (0.439, 1.714)   0.683                  4       0.944 (0.510, 1.748)   0.855                  4       0.932 (0.586, 1.481)   0.765                  
  Genotyping          mic-Array   2                      0.908 (0.655, 1.257)   0.560           2                      0.889 (0.581, 1.362)   0.590   3                      0.884 (0.758, 1.030)   0.115   2                      0.931 (0.752, 1.153)   0.511   2                      0.955 (0.769, 1.185)   0.673
  PCR-RFLP            5           0.788 (0.508, 1.222)   0.287                  5               0.561 (0.235, 1.336)   0.192                  5       0.691 (0.412, 1.158)   0.161                  5       0.617 (0.314, 1.212)   0.161                  5       0.744 (0.482, 1.147)   0.181                  
  Sample size         \<500       4                      0.861 (0.443, 1.677)   0.661           4                      0.724 (0.203, 2.580)   0.619   4                      0.808 (0.372, 1.758)   0.591   4                      0.739 (0.297, 1.836)   0.515   4                      0.827 (0.453, 1.510)   0.537
  ≥500                3           0.849 (0.666, 1.083)   0.187                  3               0.620 (0.294, 1.308)   0.210                  4       0.804 (0.643, 1.005)   0.055                  3       0.696 (0.358, 1.353)   0.285                  3       0.791 (0.542, 1.154)   0.224                  
  Quality score       \<8         4                      0.853 (0.470, 1.550)   0.603           4                      0.902 (0.325, 2.507)   0.843   4                      0.868 (0.439, 1.714)   0.683   4                      0.944 (0.510, 1.748)   0.855   4                      0.932 (0.586, 1.481)   0.765
  ≥8                  3           0.855 (0.645, 1.134)   0.278                  3               0.458 (0.183, 1.148)   0.096                  4       0.749 (0.559, 1.005)   0.054                  3       0.514 (0.248, 1.063)   0.072                  3       0.676 (0.417, 1.095)   0.112                  

Among the different methods that were used to genotype samples, the mic-array results showed that CC genotype or C allele of rs701848 was associated with increased cancer risk (Table [3](#T3){ref-type="table"}). For sample sizes ≥ 500, individuals carrying CC, or combined TC/CC genotypes, or C allele in the rs701848 SNP were associated with increased cancer risk (Table [3](#T3){ref-type="table"}). In studies with quality score ≥ 8, we observed association between rs701848 SNP and cancer risk in all models except heterozygous model (Table [3](#T3){ref-type="table"}). The results of subgroup analyses by genotyping and sample size showed no significant association between rs2735343 polymorphism in PTEN with cancer risk (Table [4](#T4){ref-type="table"}).

Meta-regression analysis {#s2_5}
------------------------

We conducted meta-regression analysis based on ethnicity, cancer type, source of controls, genotyping methods, quality score (at the median cut-off point of 8), and sample size parameters to determine the factors that are critical for association of the *PTEN* SNPs with cancer risk. The data showed that cancer type determined the association between rs701848 and cancer risk (P \< 0.05), indicating that there exists genetic heterogeneity between different cancer types.

Publication bias and sensitivity analysis {#s2_6}
-----------------------------------------

We performed Egger\'s (Table [2](#T2){ref-type="table"}) and Begg\'s (Table [2](#T2){ref-type="table"}, Figure [5](#F5){ref-type="fig"}) tests to evaluate potential publication bias. The analysis showed no evidence of publication bias for all genetic models except homozygous and recessive models for rs701848. We conducted sensitivity analysis by Duval and Tweedie trim and fill method, which further confirmed that the results of this meta-analysis were statistically robust (Figure [5](#F5){ref-type="fig"}).

![Results of Begg\'s tests\
**(A)** Begg\'s funnel plots (left) and filled funnel (right) plots for recessive model of rs701848; **(B)** A. Begg\'s funnel plots (left) and filled funnel (right) plots for dominant model of rs2735343.](oncotarget-08-96290-g005){#F5}

DISCUSSION {#s3}
==========

PTEN exerts its tumor suppressor function by acting as a negative regulator of the mTOR/Akt signaling pathway \[[@R38]\]. Mutations in *PTEN* have been reported as prognostic factors in several cancers \[[@R14]--[@R17], [@R19], [@R39], [@R40]\]. Patients with homozygous intron 4 deletion in the *PTEN* gene are associated with increased risk of digestive tract cancer \[[@R41]\]. *PTEN* SNPs also play important roles in tumorigenesis. The *PTEN* rs11202586 SNP is associated with increased risk of testicular germ cell tumor \[[@R42]\]. Han *et al* showed that the *PTEN* rs3830675 SNP was associated with colorectal cancer in patients that consumed alcohol and smoked \[[@R43]\]. In this study, we systematically analyzed if rs701848 and rs2735343 SNPs increased cancer susceptibility. Our results indicated that CC genotype or C allele of rs701848 and GG genotype of rs2735343 increased the risk of cancer in Asian subjects.

Both rs701848 and rs2735343 SNPs are located in the intron and non-coding region of *PTEN* gene and increase cancer risk by probably influencing splicing, protein expression and cell cycle \[[@R44]\]. The rs701848 polymorphism influences cancer susceptibility by altering PTEN expression and reducing *PTEN* mRNA stability \[[@R29]\]. Although these functional genetic polymorphisms of *PTEN* were known to participate in tumorigenesis, their relationship with cancer risk was unknown \[[@R1]--[@R3], [@R45], [@R46]\]. Jang *et al* \[[@R23]\] and Xu *et al* \[[@R29]\] showed that C allele of rs701848 was more susceptible than the T allele in developing ESCC. In our study, we investigated 5458 cancer cases and 6003 controls and showed that the CC and CT genotypes or C allele of *PTEN* rs701848 SNP contributed to ESCC risk, especially, the individuals carrying CC genotype in PTEN rs701848 have a 1.813-fold increased cancer risk of ESCC. Our conclusion was different from Ma\'s study that investigated 206 ESCC cases and controls each and concluded that the rs701848 CC genotype was not associated with ESCC risk \[[@R24]\]. We performed subgroup analysis and did not find correlation between rs701848 and increased risk of other cancers \[[@R20], [@R21], [@R25], [@R33], [@R35]\]. Our results also showed that rs2735343 GG genotype was associated with increased cancer risk supporting Jang\'s \[[@R23]\] and Ma\'s \[[@R24]\] findings.

Cancer is a genetic disease because the underlying causes include somatic mutations, chromosome translocations, gene amplification, and epigenetic changes \[[@R47]--[@R49]\]. A single nucleotide polymorphism (SNP) can be a driver mutation in some cancer types. The accumulation of driver gene mutations are not synchronous and result in cellular heterogeneity within individual tumors \[[@R50]\]. Therefore, genetic heterogeneity is a distinguishing criterion for many cancer types. We comprehensively explored possible origins of heterogeneity by both sub-group and meta-regression analyses and demonstrated that in most genetic models our overall analyses was robust and consistent.

The major drawback of our meta-analysis was that it limited to individuals of Asian descent. Therefore, the effects of rs701848 and rs2735343 on non-Asian populations need to be studied in well-designed and large scale case-control studies. In conclusion, we demonstrate that the C allele of rs701848 and G allele of rs2735343 in PTEN gene increases cancer risk in Asian populations.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

This meta-analysis was performed according to the protocols of the *Observational Studies in Epidemiology (MOOSE) group* \[[@R51]\]. Two researchers, SDD and ZQ, independently searched the PubMed, EMBASE, Cochrane library, and Chinese National Knowledge Infrastructure (CNKI) databases for potentially eligible studies until March 31, 2017 without any language restrictions. The following combination of subjects and words were used for the searches: ("rs701848" or "rs2735343" or "polymorphism" or "variants" or "SNP") and ("PTEN" or "phosphatase and tensin homolog") and ("cancer carcinoma" or "tumor" or "tumour" or "cancer" or "cancer neoplasms" or "malignancy"). We excluded articles not meeting our eligibility criteria by screening titles and abstracts. Then, we screened the full text articles manually to identify all published studies that analyzed the relationship of *PTEN* rs701848 or rs2735343 with cancer risk.

Inclusion criteria {#s4_2}
------------------

The inclusion criteria for eligible articles were as follows: (1) the articles assessed the association between rs701848 or rs2735343 and cancer risk; (2) it was a case-control study; (3) study subjects diagnosed with malignant tumors were histologically confirmed; (4) sufficient data was available to calculate OR and the corresponding 95% CI. When the data in the articles was insufficient, we attempted to obtain the missing data from the first or corresponding authors via email.

Data extraction and quality assessment {#s4_3}
--------------------------------------

As mentioned above, two reviewers, SDD and LJH independently searched articles, extracted data and assessed the quality. If there was a controversy, a third researcher, ZQ, was involved to resolve the issue by discussion. The extracted data included first author, published year, country of origin, ethnicity, cancer type, genotyping method, characteristics of cases and controls, source of controls, and P value for HWE. The quality of studies was assessed by the Newcastle-Ottawa quality assessment scale for observational studies. The assessment scale had three categories, namely, selection, comparability, and exposure, which altogether contained eight items. A study was awarded a maximum of one point for each parameter within the selection and exposure categories. A maximum of two points were awarded for comparability. The maximum obtainable score was nine.

Statistical analysis {#s4_4}
--------------------

The control group was analyzed by chi-square test and P \> 0.05 was in accordance to HWE \[[@R52]\]. The relationship between rs701848 or rs2735343 and cancer risk was analyzed by ORs with 95% CIs in recessive (CC vs. CT+TT), dominant (TC+CC vs. TT), homozygous (CC vs TT), heterozygous (TC vs TT), and additive (C vs. T) models for rs701848 and homozygous (CC vs. GG), heterozygous (GC vs. GG), dominant (GC+CC vs. GG), recessive (CC vs. GC+GG) and additive (C vs G) models for rs2735343, respectively. Raw genotype frequency data was used to calculate the study-specific estimates of the OR without adjustments. The significance of the differences between cancer and study subjects was determined by performing Z test of pooled ORs, and P \< 0.05 was considered significant. Heterogeneity analysis was tested among studies using *I*^2^ test. A *I*^2^ \> 50% suggested heterogeneity \[[@R53]\]. A random-effects model was used if there was significant heterogeneity; otherwise, fixed-effect model was chosen for analysis. When there was significant heterogeneity, meta-regression and subgroup analyses were performed according to ethnicity, cancer type, source of controls, genotyping methods, quality score (at the median cut-off point of 8), and sample size \[[@R54]\]. The Taqman, SNPscan, multiplexed bead array, and Infinium methods of genotyping were classified as mic-Array for subgroup-analysis. Sensitivity analysis was assessed by trim and fill method to evaluate the reliability and stability of the meta-analysis results \[[@R18]\]. Publication bias was assessed qualitatively by funnel plots and quantitatively by Begg\'s \[[@R55]\] and Egger\'s \[[@R56]\] tests, respectively. A *P*\< 0.05 for Begg\'s and Egger\'s tests indicated significant publication bias. Data were analyzed using STATA 12.0 (Stata Corporation: College Station, TX, USA) and Review Manager 5.3 (Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014) software.
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==========================================
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